{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"description":"Percentage of Participants with II-IV Acute GVHD","groups":[{"description":"Patients undergo unirradiated DLI over 15-30 minutes on day 0. Patients then undergo restaging on day 28 and may undergo a second DLI after at least 4 weeks if no significant GVHD develops and disease status worsens or after at least 8 weeks if disease status is unchanged and persistent donor T-cells are documented.\n\nTherapeutic Allogeneic Lymphocytes: Given IV","id":"OG000","title":"Treatment (DLI)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"100 days after DLI","title":"Incidence of Grade II-IV GVHD in Patients Undergoing DLI Following a Non-myeloablative Transplant","type":"SECONDARY","unitOfMeasure":"percentage of participants"}